DrugPatentWatch Database Preview
Ipsen Inc Company Profile
What is the competitive landscape for IPSEN INC, and when can generic versions of IPSEN INC drugs launch?
IPSEN INC has two approved drugs.
There are twelve US patents protecting IPSEN INC drugs.
There are fifty-five patent family members on IPSEN INC drugs in twenty-three countries and four supplementary protection certificates in four countries.
Summary for Ipsen Inc
| International Patents: | 55 |
| US Patents: | 12 |
| Tradenames: | 2 |
| Ingredients: | 2 |
| NDAs: | 2 |
Drugs and US Patents for Ipsen Inc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ipsen Inc | ONIVYDE | irinotecan hydrochloride | INJECTABLE, LIPOSOMAL;INTRAVENOUS | 207793-001 | Oct 22, 2015 | RX | Yes | Yes | 9,730,891 | ➤ Sign Up | ➤ Sign Up | ||||
| Ipsen Inc | ONIVYDE | irinotecan hydrochloride | INJECTABLE, LIPOSOMAL;INTRAVENOUS | 207793-001 | Oct 22, 2015 | RX | Yes | Yes | 9,452,162 | ➤ Sign Up | ➤ Sign Up | ||||
| Ipsen Inc | ONIVYDE | irinotecan hydrochloride | INJECTABLE, LIPOSOMAL;INTRAVENOUS | 207793-001 | Oct 22, 2015 | RX | Yes | Yes | 9,339,497 | ➤ Sign Up | ➤ Sign Up | ||||
| Ipsen Inc | ONIVYDE | irinotecan hydrochloride | INJECTABLE, LIPOSOMAL;INTRAVENOUS | 207793-001 | Oct 22, 2015 | RX | Yes | Yes | 9,724,303 | ➤ Sign Up | Y | Y | ➤ Sign Up | ||
| Ipsen Inc | ONIVYDE | irinotecan hydrochloride | INJECTABLE, LIPOSOMAL;INTRAVENOUS | 207793-001 | Oct 22, 2015 | RX | Yes | Yes | 8,329,213 | ➤ Sign Up | Y | Y | ➤ Sign Up | ||
| Ipsen Inc | ONIVYDE | irinotecan hydrochloride | INJECTABLE, LIPOSOMAL;INTRAVENOUS | 207793-001 | Oct 22, 2015 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | |||||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
Expired US Patents for Ipsen Inc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Ipsen Inc | INCRELEX | mecasermin recombinant | INJECTABLE;SUBCUTANEOUS | 021839-001 | Aug 30, 2005 | 5,681,814 | ➤ Sign Up |
| Ipsen Inc | INCRELEX | mecasermin recombinant | INJECTABLE;SUBCUTANEOUS | 021839-001 | Aug 30, 2005 | 6,207,640 | ➤ Sign Up |
| Ipsen Inc | INCRELEX | mecasermin recombinant | INJECTABLE;SUBCUTANEOUS | 021839-001 | Aug 30, 2005 | 5,824,642 | ➤ Sign Up |
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
International Patents for Ipsen Inc Drugs
| Country | Document Number | Estimated Expiration |
|---|---|---|
| Canada | 2821167 | ➤ Sign Up |
| Japan | 4971142 | ➤ Sign Up |
| Poland | 2861210 | ➤ Sign Up |
| India | 11099DEN2014 | ➤ Sign Up |
| Norway | 20065532 | ➤ Sign Up |
| World Intellectual Property Organization (WIPO) | 2005107712 | ➤ Sign Up |
| Country | Document Number | Estimated Expiration |
Supplementary Protection Certificates for Ipsen Inc Drugs
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| 0885 | Netherlands | ➤ Sign Up | PRODUCT NAME: ONIVYDE - IRINOTECAN; REGISTRATION NO/DATE: EU/1/16/1130 20161018 |
| 2017000042 | Germany | ➤ Sign Up | PRODUCT NAME: LRINOTECAN SUCROSOFAT-SALZ, WIE Z.B. LRINOTECAN SUCROSOFAT-SALZ IN EINEM PEGYLIERTEN LIPOSOM WIE BEISPIELWEISE EINEM LIPOSOM, DAS 1,2-DISTEAROYL-SN- PHOSPHATIDYLCHOLIN, CHOLESTERIN UND N-(OMEGA-METHOXYPOLY(ETHYLENGLYKOL) (MOLEKULARGEWICHT 2000)OXYCARBONYL)-1,2-DISTEAROYLPHOSPHATIDYLETHANOLAMIN Z.B. IM MOLVERHAELTNIS 3:2:0,015 UMFASST.; REGISTRATION NO/DATE: EU/1/16/1130 20161014 |
| C/GB97/010 | United Kingdom | ➤ Sign Up | PRODUCT NAME: GENERIC NAME: IRINOTECANCHEMICAL NAME: (+)-(4S)-4,11-DIETHYL-4-HYDROXY-9-((4-PIPERIDINOPIPERIDINO)CARBONYLOXY)-1H-PYRANO (3',4':6,7) INDOLIZINO(1,2-B) QUINOLINE-3,14-(4H,12H)-DIONE,OPTIONALLY THE HYDROCHLORIDE SALT THEREOF AND OPTIONALLY THE TRIHYDRATE T; REGISTERED: FR 558822.2 19950505; FR 558823.9 19950505; FR 558824.5 19950505; FR 558825.1 19950505; UK 00012/0302 19961017; UK 00012/0303 19961017 |
| 2017 00030 | Denmark | ➤ Sign Up | PRODUCT NAME: IRINOTECAN SUCROSOFATE SALT, SUCH AS IRINOTECAN SUCROSOFATE SALT IN A PEGYLATED LIPOSOME, SUCH AS A LIPOSOME COMPRISING 1,2-DISTEAROYL-SN-PHOSPHATIDYLCHOLINE, CHOLESTEROL AND N-(OMEGA-METHOXY-POLY(ETHYLENE GLYCOL)...; REG. NO/DATE: EU/1 /16/1130 20161018 |
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
